Prognostic Value of Hematologic Parameters in Patients with Metastatic Renal Cell Carcinoma Using Tyrosine Kinase Inhibitors

  • Gunduz, Seyda (Department of Medical Oncology, Faculty of Medicine, Akdeniz University Antalya) ;
  • Mutlu, Hasan (Department of Medical Oncology, Faculty of Medicine, Akdeniz University Antalya) ;
  • Uysal, Mukremin (Department of Medical Oncology, Ahmet Necdet Sezer Research and Practice Hospital, Afyon Kocatepe University) ;
  • Coskun, Hasan Senol (Department of Medical Oncology, Faculty of Medicine, Akdeniz University Antalya) ;
  • Bozcuk, Hakan (Department of Medical Oncology, Faculty of Medicine, Akdeniz University Antalya)
  • Published : 2014.04.30


Background: The prognostic significance of the neutrophil-to-lymphocyte ratio for progression free survival in patients with metastatic renal cell carcinoma is unclear. Materials and Methods: We retrospectively reviewed 45 patients diagnosed with metastatic RCC previously treated with tyrosine kinase inhibitors from two centers, Akdeniz University Hospital and Afyon Kocatepe University. The prognostic value of the pretreatment neutrophil-tolymphocyte ratio, and other clinical and laboratory parameters were assessed by univariate and multivariate analysis. Results: Median progression free survival (PFS) was 13.9 months [95% CI for HR (6.88-20.91)] and overall survival figure of 16.6 months [95% CI for HR (7.23-26.03)] Univariate analysis revealed that PFS was significantly affected by hemoglobin level [p=0.013 (95% CI for HR (0.71-0.96))], eosinophil count [p=0.031 (95% CI for HR (0.20-0.92))], ratio of neutrophil lymphocytes (NLR) [p=0.007 (95% CI for HR (1.47-11.74))] and calcium level [p=0.006 (95% CI for HR (0.15-0.73))]. However, only NLR [p=0.031 (95% CI for HR (1.15-18.1))] and calcium levels [p=0.018 (95% CI for HR (0.20-18.1))] retained significance with multivariate analysis. Median PFS was 23.9 vs 8.6 months in patients with NLR ${\leq}2$ vs NLR >2 (Log rank; p= 0.040). Conclusions: This study showed that increased pretreatment NLR is an independent prognostic factor for patients with metastatic RCC using tyrosine kinase inhibitors.


  1. Al-Marrawi MY, Rini BI, Harshman GA, et al (2011). The association of clinical outcome to front-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC) patients (Pts.). J Clin Oncol, 29, 4555.
  2. AJCC Cancer Staging Manual, Seventh Edition (2010). published by Springer New York, Inc.
  3. Cohen RB, Oudard S (2012). Antiangiogenic therapy for advanced renal cell carcinoma: management of treatmentrelated toxicities. Invest New Drugs, 30, 2066-79.
  4. Dirican A, Kucukzeybek Y, Erten C, et al (2013). Prognostic and predictive value of hematologic parameters in patients with metastatic renal cell carcinoma: second line sunitinib treatment following IFN-alpha. Asian Pac J Cancer Prev, 14, 2101-5.
  5. Donskov F (2013). Immunomonitoring and prognostic relevance of neutrophils in clinical trials. Sem Cancer Biol, 23, 200-7.
  6. Ferlay J, Shin HR, Bray F, et al (2010) International Agency for Research on Cancer. The GLOBOCON Project.
  7. Hanninen LE, Kirchner H, Atzpodien J (1996). Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol, 155, 19-25.
  8. Heng DY, Xie W, Regan MM, et al (2009). Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factortargeted agents: results from a large, multicenter study. J Clin Oncol, 27, 5794-9.
  9. Kapoor AK, Hotte SJ (2007). Current status of cytokine therapy in management of patients with metastatic renal cell carcinoma. Can Urol Assoc J, 1, 28-33.
  10. Mathew A, Devesa SS, Fraumeni JF, et al (2002). Global increases in kidney cancer incidence, 1973-1992. Eur J Cancer Prev, 11, 171-8.
  11. Motzer RJ, Hutson TE, Tomczak P, et al (2007). Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med, 356, 115-24.
  12. Motzer RJ, Michaelson MD, Redman BG, et al (2006). Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol, 24, 16-24.
  13. Motzer RJ, Hutson TE, Olsen MR, et al (2011). Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continupus dosing schedule as first-line therapy of metastatic renal cell carcinoma: renal EFFECT trial. J Clin Oncol, 29, 308.
  14. Ohno Y, Nakashima J, Ohori M, et al (2010). Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma. J Urol, 184, 873-8.
  15. Ohno Y, Nakashima J, Ohori M, et al (2012). Followup of neutrophil-to-lymphocyte ratio and recurrence of clear cell renal cell carcinoma. J Urol, 187, 411-7.
  16. Porta C, Procopio G, Carteni G, et al (2011). Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. BJU Int, 108, 250-7.
  17. Sternberg CN, Davis ID, Mardiak J, et al (2010). Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol, 28, 1061-8.
  18. Unal D, Eroglu C, Kurtul N, Oguz A, Tasdemir A (2013). Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis? Asian Pac J Cancer Prev, 14, 5237-42.
  19. Zheng YB, Zhao W, Liu B, et al (2013). The blood neutrophil-tolymphocyte ratio predicts survival in patients with advanced hepatocellular carcinoma receiving sorafenib. Asian Pac J Cancer Prev, 14, 5527-31.
  20. Yang JC, Sherry RM, Steinberg SM, et al (2003). Randomized study of high-dose and low-dose interleukin-2 in patients withmetastatic renal cancer. J Clin Oncol, 21, 3127-32.
  21. Willett CG, Boucher Y, di Tomaso E, et al (2004). Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med, 10, 145.

Cited by

  1. Treatment of Metastatic Colorectal Cancer With or Without Bevacizumab: Can the Neutrophil/Lymphocyte Ratio Predict the Efficiency of Bevacizumab? vol.15, pp.12, 2014,
  2. Factors Prognostic for Survival in Japanese Patients Treated with Sunitinib as First-line Therapy for Metastatic Clear Cell Renal Cell Cancer vol.16, pp.14, 2015,
  3. Neutrophil to lymphocyte ratio is an independent prognostic factor in patients with recurrent or metastatic head and neck squamous cell cancer vol.3, pp.4, 2015,
  4. Pretreatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with metastatic renal cell carcinoma receiving targeted therapy vol.21, pp.2, 2016,
  5. Prognostic value of pretreatment peripheral blood markers in paranasal sinus cancer: Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio vol.39, pp.4, 2016,
  6. Pretreatment neutrophil-to-lymphocyte ratio is associated with outcome of advanced-stage cancer patients treated with immunotherapy: a meta-analysis vol.67, pp.5, 2018,